Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

C.L. Braal; A. Kleijburg; A. Jager; S.L.W. Koolen; R.H.J. Mathijssen; I.C. Ramos; P. Wetzelaer; C.A. Uyl-de Groot

doi:10.1007/s40261-021-01114-6

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

C.L. Braal^*, A. Kleijburg, A. Jager, S.L.W. Koolen, R.H.J. Mathijssen, I.C. Ramos, P. Wetzelaer, C.A. Uyl-de Groot

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	163-175
Number of pages	13
Journal	Clinical Drug Investigation
Volume	42
Issue number	2
Early online date	12 Jan 2022
DOIs	https://doi.org/10.1007/s40261-021-01114-6
Publication status	Published - Feb 2022

Keywords

DOSE-ESCALATION
CYP2D6 GENOTYPE
LIFE

Access to Document

10.1007/s40261-021-01114-6Licence: CC BY-NC

Cite this

Braal, C. L., Kleijburg, A., Jager, A., Koolen, S. L. W., Mathijssen, R. H. J., Ramos, I. C., Wetzelaer, P., & Uyl-de Groot, C. A. (2022). Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial. Clinical Drug Investigation, 42(2), 163-175. https://doi.org/10.1007/s40261-021-01114-6

@article{57f1623afab74d37aff4fe53ed525940,

title = "Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial",

keywords = "DOSE-ESCALATION, CYP2D6 GENOTYPE, LIFE",

author = "C.L. Braal and A. Kleijburg and A. Jager and S.L.W. Koolen and R.H.J. Mathijssen and I.C. Ramos and P. Wetzelaer and {Uyl-de Groot}, C.A.",

year = "2022",

month = feb,

doi = "10.1007/s40261-021-01114-6",

language = "English",

volume = "42",

pages = "163--175",

journal = "Clinical Drug Investigation",

issn = "1173-2563",

publisher = "Adis International Ltd",

number = "2",

}

Braal, CL, Kleijburg, A, Jager, A, Koolen, SLW, Mathijssen, RHJ, Ramos, IC, Wetzelaer, P & Uyl-de Groot, CA 2022, 'Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial', Clinical Drug Investigation, vol. 42, no. 2, pp. 163-175. https://doi.org/10.1007/s40261-021-01114-6

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial. / Braal, C.L.; Kleijburg, A.; Jager, A.; Koolen, S.L.W.; Mathijssen, R.H.J.; Ramos, I.C.; Wetzelaer, P.; Uyl-de Groot, C.A.

In: Clinical Drug Investigation, Vol. 42, No. 2, 02.2022, p. 163-175.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

AU - Braal, C.L.

AU - Kleijburg, A.

AU - Jager, A.

AU - Koolen, S.L.W.

AU - Mathijssen, R.H.J.

AU - Ramos, I.C.

AU - Wetzelaer, P.

AU - Uyl-de Groot, C.A.

PY - 2022/2

Y1 - 2022/2

KW - DOSE-ESCALATION

KW - CYP2D6 GENOTYPE

KW - LIFE

U2 - 10.1007/s40261-021-01114-6

DO - 10.1007/s40261-021-01114-6

M3 - Article

C2 - 35020170

VL - 42

SP - 163

EP - 175

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 2

ER -